Indivior (LON:INDV) was upgraded by equities research analysts at Jefferies Financial Group to a “buy” rating in a research report issued on Monday, Stock Target Advisor reports. The brokerage currently has a GBX 200 ($2.46) target price on the specialty pharmaceutical company’s stock, up from their previous target price of GBX 70 ($0.86). Jefferies Financial Group’s price objective indicates a potential upside of 40.65% from the company’s previous close.
Separately, Citigroup upped their price objective on shares of Indivior from GBX 45 ($0.55) to GBX 85 ($1.05) and gave the stock a “neutral” rating in a research report on Wednesday, July 22nd.
Shares of INDV stock opened at GBX 142.20 ($1.75) on Monday. Indivior has a 52-week low of GBX 32.90 ($0.40) and a 52-week high of GBX 99.75 ($1.23). The company has a debt-to-equity ratio of 730.77, a quick ratio of 1.64 and a current ratio of 1.75. The company has a 50-day simple moving average of GBX 82.33 and a two-hundred day simple moving average of GBX 54.97. The company has a market capitalization of $1.04 billion and a price-to-earnings ratio of -10.51.
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Read More: QQQ ETF
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.